Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch

This article was originally published in The Gray Sheet

Executive Summary

Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.
Advertisement

Related Content

Abbott, Biocompatibles To Initiate Drug-Coated Stent Trial By Year-End
Boston Scientific Seeks To Have $324 Mil. J&J Stent Patent Award Set Aside
Biocompatibles' BiodivYsio Stent To Be Sold By Abbott's Perclose Division
Biocompatibles' BiodivYsio Stent To Be Sold By Abbott's Perclose Division
Advertisement
UsernamePublicRestriction

Register

MT015104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel